Autres langues HLS Therapeutics Inc.

Actions

HLS

CA40390B1094

Produits pharmaceutiques

Temps Différé Toronto S.E. 20:02:40 01/10/2026			Varia. 5j.	Varia. 1 janv.
3,800 ^CAD	-9,52%		-3,55%	-21,16%

24/09	HLS Therapeutics obtient l’autorisation de la Bourse de Toronto (TSX) d’augmenter son offre de rachat d’actions dans le cours normal des activités	MT
24/09	TrueCar, Inc. annonce une augmentation de son programme de rachat d’actions.	CI

Autres langues

13:01	HLS Therapeutics Announces Board of Directors Changes
24/09	HLS Therapeutics Gets TSX Acceptance to Increase Normal Course Issuer Bid
24/09	HLS Therapeutics Increases Normal Course Issuer Bid
24/09	TrueCar, Inc. announces an Increase in Equity Buyback.
12/08	HLS Therapeutics : Q2 2026 Conference Call Presentation
12/08	HLS Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
12/08	Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on June 23, 2026.
12/08	Earnings Flash (HLS.TO) HLS Therapeutics Inc. Reports Q2 Revenue $14.7M, vs. FactSet Est of $14.2M
12/08	HLS Therapeutics Announces Q2 2026 Financial Results
12/08	HLS Therapeutics Inc. Reaffirms Consolidated Earnings Guidance for 2026
05/08	HLS Therapeutics Provides Update on NILEMDO™ Market Access
29/07	HLS Therapeutics to Host Q2 2026 Financial Results Conference Call
26/06	HLS Therapeutics Reports Annual Meeting Results
23/06	HLS Therapeutics Inc. announces an Equity Buyback for 1,500,000 shares.
23/06	HLS Therapeutics to Begin its Normal Course Issuer Bid
23/06	HLS Therapeutics Announces Normal Course Issuer Bid
23/06	HLS Therapeutics Inc. authorizes a Buyback Plan.
15/05	HLS Therapeutics : First Quarter 2026 Presentation
15/05	HLS Therapeutics Q1 Net Loss Narrows on Lower Costs, Higher Revenue
15/05	Earnings Flash (HLS.TO) HLS Therapeutics Says Vascepa Net Sales Grew 15% In Q1, Strongest Quarterly Growth Since Q2 2025
15/05	Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on March 13, 2025.
15/05	HLS Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
15/05	HLS Therapeutics 2026 Financial Guidance Reaffirmed; Revs of US$56-60M and Adjusted EBITDA of $18.5-21M
15/05	HLS Therapeutics Cites NILEMDO Full Commercial Launch in April
15/05	HLS Therapeutics Q1 2026 Revenue of US$12.9 million, up 2% YoY